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Abstract
Carﬁlzomib, a selective proteasome inhibitor (PI), is approved for the treatment of patients with relapsed or refractory
multiple myeloma (MM). Combination regimens incorporating a PI and immunomodulatory drug (IMiD) have been
associated with deep responses and extended survival in patients with newly diagnosed MM (NDMM). Carﬁlzomib-based
combinations with immunomodulators are being extensively studied in the frontline setting. The objective of this review was
to describe efﬁcacy and safety data for carﬁlzomib-based, PI/immunomodulatory combinations in NDMM. Information
sources were articles indexed in PubMed and abstracts from key hematology/oncology congresses published between
January 2012 and December 2018. PubMed and congresses were searched for prospective clinical studies assessing the
combination of carﬁlzomib with an IMiD for NDMM treatment. Retrospective and preclinical reports, case reports/series,
reviews, and clinical studies not evaluating carﬁlzomib–immunomodulator combinations in NDMM were excluded based on
review of titles and abstracts. A total of nine articles and 72 abstracts were deemed relevant and included in the review. A
total of six distinct carﬁlzomib-based, PI/immunomodulator combination regimens have been evaluated in 12 clinical trials.
Overall, treatment with these regimens has resulted in deep responses, including high rates of negativity for minimal residual
disease. These deep responses have translated to long progression-free survival and overall survival rates. Efﬁcacy results for
these regimens have generally been consistent across subgroups deﬁned by age, transplant eligibility, and cytogenetic risk.
The safety proﬁle of carﬁlzomib in NDMM is consistent with that observed in the relapsed-refractory MM setting. Clinical
studies have found that carﬁlzomib-based combinations with immunomodulators are highly active with a favorable safety
proﬁle in NDMM. The carﬁlzomib, lenalidomide, and dexamethasone (KRd) drug backbone is a promising foundation for
treatment strategies aimed at achieving long-term, deep responses (functional cures) in the frontline setting. Several ongoing
studies are evaluating KRd, with or without anti-CD38 monoclonal antibodies.
Introduction
There were 138,509 new multiple myeloma (MM) cases
worldwide in 2016; in the United States, 30,770 projected
cases occurred in 2018 [1, 2]. The global incidence has
increased sharply in recent decades, in part due to aging
populations [1].
For newly diagnosed MM (NDMM) patients, the intro-
duction of proteasome inhibitors (PIs) and immunomodu-
latory drugs (IMiDs) has improved treatment responses
versus older therapies [3]. Several modern combination
regimens incorporating a PI–IMiD backbone are considered
recommended frontline regimens by the National Compre-
hensive Care Network and the European Society for
Medical Oncology. These clinical regimens build off
preclinical evidence showing that PIs and IMiDs have
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synergistic activity mediated by enhanced proteasome tar-
geting, caspase activation, NF-κB inhibitory activity, and
downregulation of CRBN/IRF4/MYC signaling and MCL1
[4–6]. These modern combination regimens have been
associated with deep responses and improved progression-
free survival (PFS) and overall survival (OS) [7].
Carﬁlzomib is a selective, second-generation PI that
irreversibly binds the proteasome [8, 9]. This agent exerts
its antimyeloma activity through several actions including
unfolded protein stress response induction [10], NF-κB
prosurvival activity downregulation [11], modiﬁcation of
bone turnover and the bone marrow microenvironment
leading to increased bone strength and compromised
microenvironmental support for myeloma cells [12–14],
and induction of immunogenic myeloma cell death through
increased natural kill cell-mediated MM-cell lysis and
enhanced antigen presentation (Fig. 1) [12–17]. Carﬁlzomib
has a structure (tetrapeptide epoxyketone) differentiated
from the ﬁrst-generation PI bortezomib (dipeptide boronate)
[8]. Preclinical studies demonstrated that carﬁlzomib over-
comes bortezomib resistance [9] and that it does not reduce
neurite length or inhibit nonproteasomal targets like HtrA2/
Omi, effects which were observed with bortezomib [8].
Carﬁlzomib elicits deeper and more sustained proteasome
inhibition versus bortezomib [18].
In MM clinical trials, carﬁlzomib-based regimens
demonstrated robust efﬁcacy and carﬁlzomib showed
single-agent activity; it is approved for treatment of
relapsed or refractory MM (RRMM). The approvals of
carﬁlzomib-based combination therapy were based on three
randomized phase 3 relapsed and/or refractory MM studies:
ASPIRE, ENDEAVOR, and A.R.R.O.W. In ASPIRE
and ENDEAVOR, treatment with carﬁlzomib-based regi-
mens (ASPIRE: carﬁlzomib–lenalidomide–dexamethasone
[KRd]; ENDEAVOR: carﬁlzomib–dexamethasone [Kd])
resulted in superior PFS, OS, depth of response, and health-
related quality of life (QoL) versus recent standards of care
in patients with RRMM [19–24]. In A.R.R.O.W., treatment
with a more convenient once-weekly Kd regimen (carﬁl-
zomib 70 mg/m2) improved PFS and health-related QoL
compared with twice-weekly Kd (carﬁlzomib 27 mg/m2) in
patients with relapsed and refractory MM [25, 26].
Given the established efﬁcacy of carﬁlzomib in RRMM
and the frontline potency of regimens incorporating
a PI–IMiD backbone, recent NDMM clinical trials
have evaluated combination regimens using carﬁlzomib-
based, PI–IMiD combinations. This systematic review
summarizes the efﬁcacy and safety of these regimens
for NDMM.
Methods
Studies were collected from a search of PubMed and
abstracts from key hematology/oncology congresses pub-
lished between January 2012 and December 2018. The
following congresses were systemically searched between
January 2012 and December 2018: American Society of
Fig. 1 Mechanisms of action for carﬁlzomib [12–17]. ER endoplasmic
reticulum, HLA human leukocyte antigen, MM multiple myeloma,
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells,
NK natural killer, UPR unfolded protein response
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Hematology Annual Meeting, American Society of Clinical
Oncology Annual Meeting, European Hematology Asso-
ciation Annual Congress, Blood and Marrow Transplanta-
tion Tandem Meeting, European Society for Medical
Oncology Annual Congress, International Myeloma
Workshop, and the Lymphoma & Myeloma Congress.
PubMed and congresses were searched for prospective
clinical studies that assessed the combination of carﬁlzomib
with an IMiD in NDMM patients. Speciﬁc search terms
included “carﬁlzomib,” “Kyprolis,” “MM,” “thalidomide,”
“lenalidomide,” “pomalidomide,” “newly diagnosed,”
“transplant-eligible,” and “transplant-ineligible.” Three
hundred and eighty-four articles were identiﬁed and were
screened for relevancy to this review based on titles and
abstracts. Retrospective and preclinical reports, case reports/
series, reviews, and clinical studies not evaluating frontline
carﬁlzomib-immunomodulator combinations were exclu-
ded. Nine articles were deemed relevant for inclusion
(Fig. 2a). Six hundred and ﬁfty-ﬁve abstracts were identi-
ﬁed, 72 of which were deemed relevant (Fig. 2b).
Results
Activity of carﬁlzomib–IMiD combinations in NDMM
To date, six distinct carﬁlzomib–IMiD combinations have
been assessed in 12 NDMM clinical trials [27–51]. Key
study information and efﬁcacy data (including minimal
residual disease [MRD] and MRD limit of detection) are
summarized in Tables 1 and 2 and described below. All
studies assessed twice-weekly carﬁlzomib unless stated
otherwise.
Carﬁlzomib–lenalidomide–dexamethasone
In NDMM, KRd has been examined in six distinct clinical
studies. In 2012, the MM Research Consortium (MMRC)
reported ﬁndings from a phase 1/2 study of KRd (n= 53;
transplant-eligible or -ineligible) [27]. Patients received
KRd induction until disease progression or unacceptable
toxicity for up to eight cycles (carﬁlzomib 20, 27, or
36 mg/m2 in phase 1; 36 mg/m2 in phase 2). Transplant-
eligible patients who achieved ≥partial response (PR) after
cycle 4 had stem cell collection (SCC) and the option to
proceed with autologous stem cell transplantation (ASCT),
but per protocol, were to resume KRd after SCC. After
eight cycles, patients received KRd maintenance for a
maximum of 24 total KRd cycles. After four cycles, 38%
of patients achieved ≥near complete response (nCR;
deﬁned as no detectable M protein on electrophoresis
independent of immunoﬁxation status, stable bone disease,
and normal serum calcium concentration; phase 2 primary
endpoint). At a median follow-up of 13 months (median
treatment duration, 12 cycles), overall response rate (ORR)
was 98% including 42% with a stringent complete
response (sCR). Approximately two-thirds of patients who
completed ≥8 cycles achieved sCR. Among patients
with a complete response (CR/suspected CR), the MRD-
negativity rate was 91% (multiparametric ﬂow cytometry
[MFC]). Notably, deep responses were obtained with KRd
alone as the seven patients who proceeded to ASCT were
censored for best response at the time of proceeding to
transplant because they did not resume KRd. PFS rates
were 97% and 92% at 12 and 24 months, respectively.
There were no major efﬁcacy differences between stan-
dard- and high-risk cytogenetics subgroups, although
numbers were limited (standard risk, n= 34; high risk,
n= 17). In a subgroup analysis of the MMRC study
evaluating elderly patients (age ≥65 years; n= 23), the
≥very good PR (VGPR) rate was 91%; the sCR rate
was 65% [28]. Updated MMRC study results (median
follow-up, 4 years) showed that extended KRd treatment
increased sCR rates from 42 to 51% [29]. The 2- and
4-year PFS rates were 92% and 69%, respectively [29].
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Fig. 2 Identiﬁcation of relevant manuscripts (a) and congress abstracts
(b). Duplicates and preclinical publications were ﬁltered














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Carﬁlzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma 2133
A phase 2 study National Institutes of Health (NIH)
Clinical Center study evaluated KRd in transplant-eligible
or -ineligible patients with NDMM (n= 45) or smoldering
MM (SMM) at high risk of progression (n= 12) [30].
Patients received eight KRd cycles then lenalidomide
maintenance. Carﬁlzomib (36 mg/m2) was administered for
the ﬁrst 3 weeks of a 4-week cycle. Deep responses were
observed, with 62% (NDMM) and 100% (SMM) of patients
achieving ≥nCR [30]. The 1-year PFS rate in NDMM was
95% and all NDMM patients remained alive [30]. Thirty-
four of 45 enrolled NDMM patients (76%) achieved MRD-
negative status (MFC). MRD-negativite ≥nCR rates by
MFC were 100% (NDMM) and 92% (SMM); MRD-
negativity rates by next-generation sequencing (NGS) were
67% and 75%, respectively [30]. MRD negativity was
observed In hematopoietic progenitor cell grafts from 29/30
patients [31]. In a 5-year follow-up of the study (NDMM
cohort), the MRD-negative CR rate was 62%; median time
to progression was 67.3 months and the 6-year OS rate was
84% [32]. Depth of response and PFS were consistent
regardless of age (≥65 vs <65 years) or cytogenetic risk
[30, 32]. The NIH Clinical Center study was recently reo-
pened for enrollment with expanded sample size. Based on
results from the MMRC and NIH Clinical Center studies,
KRd is a treatment option for transplant-eligible and
-ineligible patients according to the National Comprehen-
sive Care Network guidelines.
Although extended KRd treatment without transplant in
the MMRC study showed strong clinical beneﬁt, some
patients experienced progression [27]. Therefore, a second
phase 2 MMRC study added ASCT to KRd to evaluate if
further improvement of outcomes was possible [33, 34]. In
this study (n= 76), patients received four 28-day cycles of
KRd induction followed by ASCT. Following ASCT,
patients received four cycles of KRd consolidation and then
KRd maintenance for 10 cycles. Carﬁlzomib was adminis-
tered at 20/36 mg/m2. Response rates were 91% ≥VGPR,
78% ≥CR, and 75% sCR (primary endpoint) [33, 34].
Postconsolidation MRD-negative ≥CR rates were 67%
(NGS) and 95% (MFC) [34]. High rates of MRD negativity
after consolidation were found to be sustained through to
cycle 18 and after lenalidomide maintenance; this sustained
MRD negativity (cycle 18) correlated with 3-year PFS and
OS rates [34]. The 3-year PFS and OS rates for sustained
MRD negativity patients by NGS were 94 and 100%, which
were higher than those in the overall population (PFS, 86%;
OS, 93%) [34]. Similar ﬁndings were observed in patients
with high-risk disease (n= 27) [34].
The Intergroupe Francophone du Myelome also con-
ducted a phase 2 study evaluating KRd with ASCT [35].
Patients received four KRd induction cycles, ASCT, four
KRd consolidation cycles, and 1-year lenalidomide main-
tenance. Carﬁlzomib (20/36 mg/m2) was given for 3 weeks
of each 4-week cycle. Postconsolidation ORR was 89%,
including 85% ≥VGPR and 61% ≥CR. MRD-negativity rate
was 70% by ﬂow cytometry. Median PFS was not reached;
the 2-year PFS rate was 91%.
The high rates of MRD negativity observed with KRd
and integration of MRD assessments into standardized
response criteria [3] provided rationale for an ongoing
phase 1/2 study that is the ﬁrst to evaluate MRD status as
a guide for KRd treatment duration in NDMM
patients [36]. During phase 1, patients receive carﬁlzomib
(45 or 56 mg/m2) with lenalidomide–dexamethasone to
determine the maximum tolerated dose (MTD) of carﬁl-
zomib. Patients who achieve MRD negativity after any
cycle receive two additional KRd cycles before treatment
discontinuation, whereas MRD-positive patients continue
therapy for ≤12 cycles, or until disease progression or
unacceptable toxicity. The phase 2 primary endpoint is
MRD negativity at the MTD. Phase 1 results established
the carﬁlzomib MTD at 56 mg/m2. The phase 2 portion of
the study is ongoing.
The demonstrated activity of KRd and the promising
efﬁcacy of carﬁlzomib–cyclophosphamide–dexamethasone
(KCd) [37] in NDMM patients provided the rationale for
the randomized FORTE trial, where NDMM patients were
randomized 1:1:1 to four 28-day KCd cycles followed by
ASCT and four KCd consolidation cycles; or four 28-day
KRd cycles followed by ASCT and four KRd consolidation
cycles; or twelve KRd cycles [38]. Patients who complete
consolidation are randomized to lenalidomide versus
carﬁlzomib–lenalidomide maintenance. Carﬁlzomib was
administered at 20/36 mg/m2. A total of 474 patients were
randomized (KRd+ASCT, n= 158; KCd+ASCT, n=
159; KRd 12 cycles, n= 157). Premaintenance, ≥VGPR
and sCR rates were higher in the KRd arms than in the KCd
arm (KRd+ASCT, 89 and 44%; KCd+ASCT, 76 and
32%; KRd 12 cycles, 87 and 43%). MRD-negativity rates
were also higher with KRd versus KCd (KRd+ASCT,
58%; KCd+ASCT, 42%; KRd 12 cycles, 54%). These
beneﬁts for KRd versus KCd were consistent, regardless of
the presence of high-risk disease. The sCR rates in the KRd
arms also compare favorably with the postconsolidation
sCR rate (28.9%) reported for the daratumumab–
bortezomib–thalidomide–dexamethasone arm in the phase 3
CASSIOPEIA study of this combination in transplant-
eligible NDMM [52].
Inspired by the NIH Clinical Center study, the ongoing
phase 2 GEM-CESAR trial is assessing KRd induction and
consolidation with ASCT for SMM at high risk of pro-
gression. Preliminary post-ASCT efﬁcacy results (69%
≥CR; 58% MRD negative) demonstrate the promise of this
approach [39]. An EMN-MSKCC randomized phase
2 study comparing KRd versus Rd in high-risk SMM has
recently started.
2134 O. Landgren et al.
Overall, the safety proﬁle of KRd in NDMM patients has
been consistent with the proﬁle observed in the ASPIRE
study. In the FORTE trial, rates of treatment discontinuation
due to adverse events (AEs) and fatal AEs were 8 and 1%,
whereas in ASPIRE these rates were 15% and 7%,
respectively (see Tables 3 and 4 for additional details)
[24, 38, 40].
Carﬁlzomib–thalidomide–dexamethasone
CARTHADEX was a phase 1/2 trial that evaluated
carﬁlzomib–thalidomide–dexamethasone (KTd) as induc-
tion and consolidation therapy in transplant-eligible NDMM
patients. During KTd induction, patients received four
cycles of carﬁlzomib 20/27, 20/36, 20/45, or 20/56 mg/m2.
In the overall population (N= 91), KTd induction resulted
in an ORR of 90%, including a CR in 25% of patients and
a ≥VGPR (primary endpoint) in 68% of patients [41].
Response rates improved with transplant and KTd con-
solidation (Table 2). After consolidation, patients with
standard- and high-risk disease showed no difference in
≥VGPR rates and had similar CR rates. At a median follow-
up of 23 months, the median PFS was not reached and the
3-year PFS rate was 72%. A subsequent update of the
CARTHADEX trial assessed the impact of prolonged KTd
induction therapy (eight cycles) at carﬁlzomib 56 mg/m2 on
depth of response [42]. Patients treated with prolonged KTd
induction (n= 26) had higher ≥VGPR and ≥CR rates at end
of induction compared with those treated with four KTd
induction cycles at 56 mg/m2 (n= 20). However, depth
of response between the two groups was noted to be similar
after completion of ASCT and consolidation [42]. Another
update of the CARTHADEX trial found that post-
consolidation sCR and VGPR rates were numerically higher
for the 36–56 versus 27 mg/m2 carﬁlzomib dose levels, but
that PFS/OS were similar between these doses [43].
Carﬁlzomib–cyclophosphamide–thalidomide–
dexamethasone
The phase 1/2 CYKLONE trial (N= 64) examined a
four-drug regimen termed CYKLONE (carﬁlzomib–
cyclophosphamide–thalidomide–dexamethasone) for the
treatment of transplant-eligible NDMM patients [44]. The
MTD of carﬁlzomib in CYKLONE was 20/36 mg/m2
(phase 1 primary endpoint). The ORR across all treatment
cycles and dose levels was 91%. At the MTD, the ≥VGPR
rate after four cycles was 59% (phase 2 primary endpoint).
The safety of carﬁlzomib–thalidomide combinations
(KTd and CYKLONE) was consistent with previously
reported safety of both agents. Lack of overlapping toxi-
cities (especially neuropathy) between these two agents
allowed a favorable safety proﬁle for these regimens.
Carﬁlzomib–clarithromycin–lenalidomide–dexamethasone
Combination treatment with the antibiotic clarithromycin
plus a PI has been found preclinically to induce synergistic
cytotoxicity [45, 46]. The phase 2 Car-BiRD study (N= 72)
of carﬁlzomib–clarithromycin–lenalidomide–dexamethasone
(Car-BiRD) evaluated carﬁlzomib as part of a sequential
treatment strategy: Kd induction (until maximal response)
followed by BiRD consolidation and lenalidomide main-
tenance for transplant-eligible or -ineligible NDMM patients
[47]. Carﬁlzomib (30-min IV infusion) was given for the ﬁrst
3 weeks of each 4-week cycle at a dose of 20/45mg/m2
(ﬁrst 26 patients) or 20/56mg/m2 (thereafter). Kd induction
resulted in an ORR of 91%, ≥VGPR rate of 71%, and a ≥CR
rate of 13%. Following BiRD consolidation, ORR, ≥VGPR,
and ≥CR rates improved to 100%, 95%, and 28%, respec-
tively. Lenalidomide maintenance further improved depth of
response in 19% of patients.
Carﬁlzomib–cyclophosphamide–lenalidomide–
dexamethasone
In the phase 3 UK NCRI Myeloma XI trial, transplant-
eligible patients were randomized to the upfront PI-based
quadruplet induction regimen of carﬁlzomib–cyclopho-
sphamide–lenalidomide–dexamethasone (KCRd), or triplet
induction therapy (cyclophosphamide–lenalidomide–
dexamethasone [CRd] or cyclophosphamide–thalidomide–
dexamethasone [CTd]) [48]. Patients in the triplet
induction arms could have received a second induction
with bortezomib–cyclophosphamide–dexamethasone (VCd)
before ASCT depending on post ﬁrst induction maximum
response (≥VGPR, no second induction; PR or minor
response, randomized to VCd or nothing; stable or pro-
gressive disease, VCd as second induction). Carﬁlzomib
20/36 mg/m2 was administered twice weekly for the ﬁrst
3 weeks of each 4-week cycle. A total of 1056 patients
underwent induction randomization (CTd, n= 265; CRd,
n= 265; KCRd, n= 526). Deeper responses with
carﬁlzomib-based quadruplet versus IMiD-based triplet
treatment were observed at the end of ﬁrst induction: the
≥VGPR rate at end of initial induction was 82.3% for KCRd
versus 52.8 and 64.9% for CTd and CRd, respectively.
This difference in depth of response was sustained until
≥100 days post-ASCT.
The quadruplet combination was well tolerated in
this large phase 3 trial [48]. Grade ≥3 neutropenia
occurred in 16% of KCRd patients, compared with 13%
for CTd and 22% for CRd. Grade ≥2 sensory neuropathy
rates were lower in the KCRd and CRd arms compared
with the CTd arm (~2% vs ~10%). The incidences of any-
grade cardiac failure and hypertension in the KCRd arm
were both <2%.
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Carﬁlzomib–lenalidomide–dexamethasone plus
daratumumab
The phase 1b MMY1001 study evaluated KRd-
daratumumab in NDMM patients [49, 50]. Patients were
treated with this combination for ≤ 13 treatment cycles or
until discontinuation for ASCT. Carﬁlzomib (20/70 mg/m2)
was administered once weekly. This combination (n= 21)
resulted in an ORR of 100% with 91 and 57% of patients
achieving ≥VGPR and ≥CR, respectively. The 1-year PFS
rate was 95%.
An ongoing phase 2 trial is evaluating MRD using blood
and bone marrow-based assays after KRd-daratumumab
treatment for NDMM. Preliminary results showed the fea-
sibility of longitudinal MRD tracking in three patients who
completed the MRD assays [51].
The phase 2 ASCENT trial (NCT03289299) is assessing
the feasibility of KRd-daratumumab induction for high-
risk SMM.
Safety of carﬁlzomib–IMiD combinations in NDMM
The safety proﬁle of carﬁlzomib has been well established
in RRMM, where it has shown to have manageable AEs
[53] and a favorable beneﬁt-risk proﬁle given the observed
PFS/OS advantage. In this setting, the most common grade
3/4 AEs associated with single-agent carﬁlzomib were pri-
marily hematologic [54]. Cardiovascular events have also
been associated with carﬁlzomib, with hypertension (mainly
grades 1 and 2) being the most common type. In a pooled
analysis of phases 1–3 RRMM clinical studies (n= 2044
carﬁlzomib-exposed patients), any-grade and grade ≥3
hypertension rates were 18.5% and 5.9%, respectively, and
any-grade and grade ≥3 cardiac failure rates were 6.7% and
4.4%, respectively [55]. Carﬁlzomib-associated cardiovas-
cular events have been found to be generally reversible and
manageable, as reﬂected by relatively low carﬁlzomib dis-
continuation rates across studies [55–57]. Furthermore, the
efﬁcacy beneﬁt of carﬁlzomib in terms of reduction in
the risk of progression/death has been found to outweigh the
risks observed with carﬁlzomib (including cardiac failure or
hypertension) among RRMM patients [55].
Carﬁlzomib has been associated with low rates of per-
ipheral neuropathy (PN) in RRMM, an AE associated with
bortezomib that may impair QoL and limit treatment duration
[58]. The low rate of PN with carﬁlzomib is consistent with
preclinical results showing that in contrast to bortezomib,
carﬁlzomib has minimal activity against nonproteasomal
proteases, including the stress-induced, prosurvival protease
HtrA2/Omi [8]. This selectivity may explain the difference in
PN incidence between the carﬁlzomib and bortezomib arms
in ENDEAVOR [19]. In ASPIRE, addition of carﬁlzomib to


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2138 O. Landgren et al.
The safety proﬁle of carﬁlzomib–IMiD combination
therapy in NDMM patients has been consistent with the
known safety proﬁle of carﬁlzomib. Below, we summarize
the above AEs of interest observed in the large, randomized
NDMM studies (FORTE and Myeloma XI). General safety
and AEs of interest for all NDMM studies are shown in
Tables 3 and 4.
Hematologic adverse events
Hematologic events were the most common AEs observed
in frontline clinical trials of carﬁlzomib–IMiD combinations
(Table 4). The largest datasets come from the FORTE and
Myeloma XI trials. In the FORTE trial, 18–22% of KRd
patients had ≥1 grade ≥3 or serious hematologic AE [38].
Hematologic AE rates were comparable for KRd and KCd
(18–22% vs 17%). In the KCRd arm of the Myeloma XI
trial, rates of grade ≥3 neutropenia and thrombocytopenia
were 16.4%, and 8.4%, respectively [48].
Peripheral neuropathy
Consistent with ﬁndings in RRMM, carﬁlzomib-based
combination therapy has been associated with a low
incidence of grade ≥2 PN in NDMM and a low rate of
carﬁlzomib discontinuation or dose reductions due to PN
(Table 4). In the KCRd arm of the Myeloma XI trial, grade
≥2 motor and sensory neuropathy rates were ~3% each [48].
PN rates have not been reported for the FORTE trial.
Cardiovascular events
Cardiovascular events have been reported with
carﬁlzomib–IMiD combinations in the frontline setting
(Table 4). In the FORTE trial, the rate of grade 3/4 or
serious cardiac events was 2–3% in the KRd arms and 3%
in the KCd arm [38]. Hypertension (grade 3/4, or serious in
severity) was reported in 8% of patients who received 12
KRd cycles and in 3% patients who received KRd or KCd
with ASCT [38]. In the KCRd versus CRd versus CTd arms
of the phase 3 Myeloma XI study, any-grade arrhythmia,
heart failure, and hypertension were reported in approxi-
mately 2.3% versus 1% versus 1.5%, 1% versus 0% versus
0%, and <1% versus <1% versus <1% of patients [48].
Although cardiovascular events have been observed with
carﬁlzomib, they appear to be manageable and reversible in
the majority of cases [56]. Importantly, grade ≥3 heart
failure rates are relatively low considering carﬁlzomib
efﬁcacy. Clinical experience with carﬁlzomib has aided
development of strategies for managing and mitigating
cardiovascular events [56, 57]; clinical guidelines have been
developed in collaboration with cardiologists to minimize
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Conclusions
Carﬁlzomib-based, PI–IMiD combination therapies have
been shown to be highly efﬁcacious with a favorable
safety proﬁle in NDMM, as evidenced by the data from
several studies (single-arm and randomized) reviewed
above. These regimens elicit deep and durable responses,
including MRD negativity, which have translated to high
PFS and OS rates. Furthermore, a consistent beneﬁt for
these regimens has been observed across patient seg-
ments, including in both transplant-eligible and -ineligible
patients, across age subgroups, and regardless of cytoge-
netic risk. To date, results have been reported from only
one randomized phase 3 study of carﬁlzomib-based IMID
combination therapy in NDMM, and there are currently
no phase 3 data for how these therapies directly compare
with the most recent frontline standards of care. Future
data from such studies will be important for evaluating the
role of carﬁlzomib-based, PI–IMiD combination therapy
in NDMM.
Bortezomib-based, PI–IMiD triplet combinations are
considered standards of care in the frontline setting. For
example, VRd is considered a preferred regimen by the
NCCN for transplant-eligible and -ineligible patients based
on data showing that this regimen improved PFS and OS
compared with Rd. Despite the absence of controlled and
randomized trials, carﬁlzomib-based, PI–IMiD combina-
tions may offer several advantages relative to this standard
of care. For some patients, PN associated with bortezomib
may interrupt treatment, resulting in suboptimal response
and QoL. These patients may beneﬁt from a carﬁlzomib-
based PI–IMiD regimen. Although there are currently no
head-to-head data of carﬁlzomib- versus bortezomib-based,
PI–IMiD therapy in NDMM, KRd (without or without
ASCT) is one of the most active frontline regimens
observed in NDMM studies [27–36, 38–40, 60]. Pre-
liminary data from the observational CoMMpass study
(NCT01454297) suggest that improved response rates and
longer event-free survival are associated with KRd versus
VRd in NDMM [61], while other preliminary data from
CoMMpass and the Flatiron observational study suggest
longer treatment duration with VRd [62]. However, these
ﬁndings need to be validated in a prospective manner. The
ongoing, randomized phase 3 ENDURANCE study
(NCT01863550; N= 1000+), which is evaluating KRd
versus VRd, will provide important head-to-head data
regarding the beneﬁt-risk proﬁles of carﬁlzomib- versus
bortezomib-based PI–IMiD therapy in NDMM, with the
limitation of capping carﬁlzomib treatment duration to nine
cycles.
Carﬁlzomib has been associated with manageable and
reversible cardiovascular events in RRMM, and these
events merit monitoring in NDMM. In a meta-analysis of
NDMM and RRMM patients (N= 2594), any-grade and
grade ≥3 congestive heart failure rates were 4.1% and 2.5%,
respectively [63].
The introduction of new antimyeloma agents has sig-
niﬁcantly improved the outlook of MM patients; however,
MM remains an incurable disease. To achieve long-term
remissions or even functional cure for NDMM patients, the
most potent agents need to be used upfront. Based on
favorable clinical outcomes of carﬁlzomib therapies in the
relapsed setting, we believe that a carﬁlzomib–IMiD com-
bination will also beneﬁt NDMM patients. Ongoing front-
line studies are evaluating the impact of adding new drugs
with novel mechanisms, such as monoclonal antibodies, to
the carﬁlzomib–IMiD combination to achieve functional
cures in MM.
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